Program
mitiglinide
Also written as “Mitiglinide”, “KAD-1229” and “mitiglinide and metformin”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kissei Pharmaceutical | 30 open or running | phase 4since May 30, 2014 | Apr 17, 2007 | none ahead |
| JW Pharmaceutical | 20 open or running | phase 4since Apr 18, 2008 | Apr 18, 2008 | none ahead |
| Elixir Pharmaceuticals | 10 open or running | phase 3since Aug 20, 2007 | Aug 20, 2007 | none ahead |
| Orient Europharma | 10 open or running | phase 4since Mar 3, 2020 | Mar 3, 2020 | none ahead |
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 17, 2007First study: phase 3 study in Diabetes MellitusNew to Kissei PharmaceuticalKissei Pharmaceutical · NCT00461617 · 291 enrolled
- Aug 20, 2007Elixir Pharmaceuticals's first study: phase 3 study in Diabetes Mellitus, Type 2New to Elixir PharmaceuticalsElixir Pharmaceuticals · NCT00519142 · 367 enrolled · United States, Puerto Rico
- Apr 18, 2008JW Pharmaceutical's first study: phase 4 study in Diabetes Mellitus, Type 2New to JW PharmaceuticalJW Pharmaceutical · NCT00663884 · 167 enrolled · Korea, Republic of
- Apr 6, 2011Phase 3 study in Diabetes Mellitus, Type 2Kissei Pharmaceutical · NCT01333592 · 136 enrolled · Japan
- Sep 27, 2011Phase 1 study in HealthyJW Pharmaceutical · NCT01443221 · 24 enrolled · Korea, Republic of
- May 30, 2014Phase 4 study in Diabetes Mellitus, Type 2Kissei Pharmaceutical · NCT02154347 · 178 enrolled · Japan
- Mar 3, 2020Orient Europharma's first study: phase 4 study in Diabetes Mellitus, Type 2New to Orient EuropharmaOrient Europharma · NCT04349696 · 16 enrolled · Taiwan
TargetBeta
“Sulfonylurea receptor 1, Kir6.2 blocker”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| repagliniderule | Novo Nordisk | phase 4 | 32 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04349696Diabetes Mellitus, Type 2 · Taiwan | 4 | Completed | Orient Europharma | Apr 2018 | 16 |
| NCT02154347Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Kissei Pharmaceutical | Jul 2016 | 178 |
| NCT01443221Healthy · Korea, Republic of | 1 | Completed | JW Pharmaceutical | Jan 2011 | 24 |
| NCT01333592Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Kissei Pharmaceutical | Aug 2012 | 136 |
| NCT00663884Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Jul 2009 | 167 |
| NCT00519142Diabetes Mellitus, Type 2 · United States, Puerto Rico | 3 | Completed | Elixir Pharmaceuticals | Oct 2008 | 367 |
| NCT00461617Diabetes Mellitus | 3 | Completed | Kissei Pharmaceutical | Jul 2007 | 291 |
How it is read
Names in the registry
- “Mitiglinide”, 4 entries
- “KAD-1229”, 2 entries
- “mitiglinide and metformin”, 2 entries
- “mitiglinide”, 2 entries
- “Mitiglinide calcium hydrate”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 6 studies
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.